Catalyst Wire Dossier Catalyst Wire Dossier

Navarixin

navarixin · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Navarixin, covering 2014-09-17 to 2022-06-29. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) [Phase 2]

See pricing